ERBB2 and inflammatory breast carcinoma: Our percentages of black patients within the three other subtypes of IBC (HR+/HER2− (14%), HR+/HER2+ (16%), and HR−/HER2+ (17%)) also were higher than the SEER study (HR+/HER2− (12%), HR+/HER2+ (7%), and HR−/HER2+ (10%)).